



PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RE APPLICATION OF:  
Patrick L. Iversen  
APPLICATION No.: 10/723,354  
FILED: November 25, 2003  
FOR: ENZYME INHIBITORS FOR METABOLIC  
REDIRECTION

EXAMINER: Epps-Ford, Janet L.  
ART UNIT: 1633  
CONF. No: 8250

**Information Disclosure Statement After First Office Action but  
Before Final Action or Notice of Allowance – 37 C.F.R. § 1.97(c)**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

1. Timing of Submission

The information transmitted herewith is being filed *after* three months of the filing date of this application or after the mailing date of the first Office action on the merits, whichever occurred last, but *before* the mailing date of either a final action under 37 C.F.R. § 1.113 or a Notice of Allowance under 37 C.F.R. § 1.311, whichever occurs first. The references listed on the enclosed Form PTO-1449 (modified) may be material to the examination of this application; the Examiner is requested to make them of record in the application.

2. Cited Information

- All cited references are U.S. patents and publications, therefore no references are enclosed.
- Copies of the following references are enclosed:
  - All cited references
  - All cited references except U.S. patents and publications
  - References marked by asterisks
  - The following:

08/10/2006 GWORDDF1 00000045 10723354

03 FC:1806

180.00 0P

- Copies of the following references can be found in parent U.S. Application No.
  - All cited references
  - References marked by asterisks
  - The following:
- The following references are not in English. For each such reference, the undersigned has enclosed: (i) a translation of the reference; (ii) a copy of a communication from a foreign patent office or International Searching Authority citing the reference; (iii) a copy of a reference which appears to be an English-language counterpart; or (iv) an English-language abstract for the reference prepared by a third party. Applicant has not verified that the translation, English-language counterpart or third-party abstract is an accurate representation of the teachings of the non-English reference, though, and reserves the right to demonstrate otherwise.
  - All cited references
  - References marked by ampersands
  - The following:

3. Effect of Information Disclosure Statement (37 C.F.R. § 1.97(h))

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the cited information is, or is considered to be, material to patentability. In addition, applicant does not admit that any enclosed item of information constitutes prior art to the subject invention and specifically reserves the right to demonstrate that any such reference is not prior art.

4. Fee Payment (37 C.F.R. § 1.97(c)) or Certification (37 C.F.R. § 1.97(e))

- Applicant elects to pay the fee under 37 C.F.R. § 1.17(p) \$180.00.
  - Check enclosed for \$180.00 (covering the fee under 37 C.F.R. § 1.17(p))
  - Please charge the above fee(s) to Deposit Account No. 50-2207 this paper is provided in triplicate.
- Applicant submits that no fee is due in light of the following certification under 37 C.F.R. § 1.97(e) (check only one):
  - In accordance with 37 C.F.R. § 1.97(e)(1), the undersigned hereby states that each item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to this filing of this statement; or

- In accordance with 37 C.F.R. § 1.97(e)(2), the undersigned hereby states that no item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c), more than three months prior to the filing of this statement.
- Please charge any underpayment for timely filing of this paper to Deposit Account No. 50-2207.

5. Patent Term Adjustment (37 C.F.R. § 1.704(d))

- The undersigned states that each item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this statement. 37 C.F.R. § 1.704(d).

Respectfully submitted,  
Perkins Coie LLP

Date: August 8, 2006

Gina C. Freschi  
Gina C. Freschi  
Registration No. 52,062

Correspondence Address:

Perkins Coie LLP  
Customer No. 22918

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		COMPLETE IF KNOWN	
		Application Number	10/723,354
Confirmation Number	8250		
Filing Date	November 25, 2003		
First Named Inventor	Patrick L. Iversen		
Group Art Unit	1633		
Examiner Name	Epps-Ford, Janet L.		
Attorney Docket No.	50450-8311.US03		

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

## OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
	2	Furge, L. et al., <i>Biochemistry and Molecular Biology Education</i> , <u>34</u> (2):66-74 (2006).	
	3	Opalinkska, J. et al. <i>Science's stke</i> , Pages 1-5 (2003).	
	4	Summerton, J. et al. <i>Antisense &amp; Nucleic Drug Development</i> <u>7</u> :63-70 (1997).	
	5	Zhang, Y. et al. <i>Antiviral Research</i> , (In Press) (2006).	

EXAMINER	DATE CONSIDERED
----------	-----------------

**\*EXAMINER:** Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Form PTO-1449 (Modified) (Use several sheets if necessary)				<b>COMPLETE IF KNOWN</b>	
				Application Number	10/723,354
				Confirmation Number	8250
				Filing Date	November 25, 2003
				First Named Inventor	Patrick L. Iversen
				Group Art Unit	1633
				Examiner Name	Epps-Ford, Janet L.
Sheet	2	of	2	Attorney Docket No.	50450-8311.US03

<b>OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published.			T
	6	Zhang, Y. et al. <i>Veterinary Microbiology</i> (In press) (2006).			

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to application(s).	